Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;29(12):1253-1263.
doi: 10.1016/j.jagp.2021.01.015. Epub 2021 Jan 27.

Cannabinoids for Agitation in Alzheimer's Disease

John D Outen  1 , M Haroon Burhanullah  1 , Ryan Vandrey  2 , Halima Amjad  3 , David G Harper  4 , Regan E Patrick  4 , Rose L May  5 , Marc E Agronin  6 , Brent P Forester  4 , Paul B Rosenberg  7
Affiliations
Review

Cannabinoids for Agitation in Alzheimer's Disease

John D Outen et al. Am J Geriatr Psychiatry. 2021 Dec.

Abstract

Agitation is a common neuropsychiatric symptom of Alzheimer's disease (AD) that greatly impacts quality of life and amplifies caregiver burden. Agitation in AD may be associated with volume loss in the anterior cingulate cortex, posterior cingulate cortex, insula, amygdala, and frontal cortex, as well as with degeneration of monoaminergic neurotransmission, disrupted circadian rhythms, and frailty. Current pharmacologic options have troubling safety concerns and only modest efficacy. There is increasing interest in cannabinoids as promising agents due to preclinical and early clinical research that suggest cannabinoids can elicit anxiolytic, antidepressant, and/or anti-inflammatory effects. Cannabinoids may relieve agitation by regulating neurotransmitters, improving comorbidities and circadian rhythms, and increasing cerebral circulation. Here we discuss the possible contributory mechanisms for agitation in AD and the therapeutic relevance of cannabinoids, including CBD and THC.

Keywords: Alzheimer's disease; CBD; THC; aggression; agitation; cannabinoids; dementia; mechanisms; neuropsychiatric symptoms.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Therapeutic Impact of Cannabinoids on Factors of Agitation in AD
A schematic representing the factors (left) which contribute to agitation in Alzheimer’s disease [Agit-AD], and the indirect positive outcomes of cannabinoids on Agit-AD (right).
See this image and copyright information in PMC

Comment in

References

    1. Gotz J, et al., An update on the toxicity of Abeta in Alzheimer’s disease. Neuropsychiatr Dis Treat, 2008. 4(6): p. 1033–42. - PMC - PubMed
    1. Alzheimer’s Association. Facts and Figures. 2020; Available from: https://www.alz.org/alzheimers-dementia/facts-figures.
    1. Younes L, et al., Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease. Front Aging Neurosci, 2019. 11: p. 74. - PMC - PubMed
    1. Hardy JA and Higgins GA, Alzheimer’s disease: the amyloid cascade hypothesis. Science, 1992. 256(5054): p. 184–5. - PubMed
    1. Goedert M, Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci, 1993. 16(11): p. 460–5. - PubMed

Publication types